GleamWall
中文EN

FRNM Freenome, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 2017526 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY59.4%
TTM EPS YoY73.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-23.7%
ROA-17.7%
ROIC (approx.)29.0%
Asset turnover—

Leverage & solvency

Liabilities / assets34.4%
Debt / equity0.00x
Current ratio12.73x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$183.49M———$1.03M———
Cost of revenue$478,000———$611,000———
Gross profit$183.01M———$424,000———
R&D expense$68.42M———$50.63M———
SG&A expense$44.63M$941,325—-$38.09M$15.05M$193,196——
Operating income$69.97M-$941,325-$858,834-$1.68M-$65.26M-$193,196-$255,958-$175,926
Interest expense$1.19M———$644,000———
Net income$60.11M-$69.03M-$63.56M-$740,568-$64.47M-$58.73M-$57.87M$841,432
EBITDA$75.67M———-$59.46M———
EPS (basic)0.60———-0.95———
EPS (diluted)0.58———-0.95———
Weighted avg. shares (diluted)103.22M———68.02M———
Balance sheet
Cash & equivalents$180.38M$437,369$567,179$78.56M$73.98M$1.34M$1.19M$76.17M
Receivables$8.82M——$1.31M————
Inventory$1.89M——$0————
Current assets$460.99M$742,154$649,657$226.49M$1.26M$1.47M$1.34M$1.24M
PP&E, net$154.54M——$155.78M————
Goodwill$10.51M——$10.51M————
Intangibles$2.49M——$3.30M————
Total assets$733.53M$85.83M$93.33M$507.05M$92.20M$91.40M$90.63M$89.90M
Current liabilities$36.20M$3.63M$2.86M$40.53M$934,557$281,154$265,572$210,811
Total liabilities$252.20M$7.08M$6.31M$406.61M$4.38M$3.73M$3.72M$3.66M
Shareholders' equity$481.33M-$26.61M$39.68M$100.44M$135.69M$197.05M$252.92M$308.56M
Shares outstanding110.87M——67.94M————
Cash flow statement
Operating cash flow-$58.27M-$129,810-$297,852-$312,878-$166,500-$147,528-$237,747-$79,769
Investing cash flow-$132.68M$8.16M$0$0$0$300,000$300,000$0
Financing cash flow$293.66M——$0$0——$0
Depreciation & amortization$5.70M———$5.80M———
Stock-based compensation$41.94M———$2.83M———

Free plan shows the latest 8 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.